Logout 
DCGI Expert Panel Approves Serum Institute's Covovax Vaccine For Children Aged 7-11: Report
Covovax vaccine has already been approved for restricted use in adults and children in the 12-17 age group.
Covovax vaccine has already been approved for restricted use in adults and children in the 12-17 age group.
The cumulative COVID-19 vaccine doses administered in the country crossed 170 crore landmark on Monday. Development of this vaccine shall be another example of vaccine production strength of our country in line with the clarion call of our prime minister 'Making in India for the World'.
Bharat Biotech has already begun clinical trials of its Covid-19 vaccine for children in the 6-12 age group. Now, Serum Institute plans to launch clinical trials of the Novavax Covid-19 vaccine for children in July.
India is likely to approve a Covid-19 vaccine for emergency use next week. Both Serum Institute of India (SII) and Bharat Biotech have submitted additional data sought by the DCGI for grant of emergency use authorisation to their vaccines.
SII has sought emergency use authorisation for the Oxford Covid-19 vaccine, Covishield, in the country citing "unmet medical needs due to the pandemic and in the interest of the public at large."
Union Health Secretary Rajesh Bhushan stated that the adverse events related to Covaxin and Covishield would not impact the timeline of Covid-19 vaccine rollout.
The Covishield volunteer was given the test dose on October 1 at Sri Ramachandra Institute of Higher Education and Research, Chennai. He is also demanding that the testing, manufacturing and the distribution of the vaccine be stopped immediately.
Currently, Serum Institute of India (SII) is conducting phase 2 and 3 trials of the Astrazeneca-Oxford vaccine at various centres across the country.
Pune based Serum Institute of India, a part of Cyrus Poonawalla Group and the world's largest manufacturer of vaccines announced today.
New meningitis vaccine that can be stored at room temp provides new hope
Covovax vaccine has already been approved for restricted use in adults and children in the 12-17 age group.
The cumulative COVID-19 vaccine doses administered in the country crossed 170 crore landmark on Monday. Development of this vaccine shall be another example of vaccine production strength of our country in line with the clarion call of our prime minister 'Making in India for the World'.
Bharat Biotech has already begun clinical trials of its Covid-19 vaccine for children in the 6-12 age group. Now, Serum Institute plans to launch clinical trials of the Novavax Covid-19 vaccine for children in July.
India is likely to approve a Covid-19 vaccine for emergency use next week. Both Serum Institute of India (SII) and Bharat Biotech have submitted additional data sought by the DCGI for grant of emergency use authorisation to their vaccines.
SII has sought emergency use authorisation for the Oxford Covid-19 vaccine, Covishield, in the country citing "unmet medical needs due to the pandemic and in the interest of the public at large."
Union Health Secretary Rajesh Bhushan stated that the adverse events related to Covaxin and Covishield would not impact the timeline of Covid-19 vaccine rollout.
The Covishield volunteer was given the test dose on October 1 at Sri Ramachandra Institute of Higher Education and Research, Chennai. He is also demanding that the testing, manufacturing and the distribution of the vaccine be stopped immediately.
Currently, Serum Institute of India (SII) is conducting phase 2 and 3 trials of the Astrazeneca-Oxford vaccine at various centres across the country.
Pune based Serum Institute of India, a part of Cyrus Poonawalla Group and the world's largest manufacturer of vaccines announced today.
New meningitis vaccine that can be stored at room temp provides new hope
